MX2022006031A - Métodos de tratamiento del cáncer con inhibidores de dkk-1. - Google Patents
Métodos de tratamiento del cáncer con inhibidores de dkk-1.Info
- Publication number
- MX2022006031A MX2022006031A MX2022006031A MX2022006031A MX2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A MX 2022006031 A MX2022006031 A MX 2022006031A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- dkk
- inhibitors
- methods
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229940097000 DKK-1 inhibitor Drugs 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un método para tratar a un sujeto que sufre de un cáncer, que comprende los pasos de obtener una muestra de una célula de cáncer del sujeto; determinar una secuencia de una proteína de subunidad catalítica de 3 - quinasa de fosfatidilinositol (PIK3CA) En la muestra; y administrar una primera cantidad de un inhibidor de DKK1 al sujeto determinado para tener la secuencia de proteína PIK3CA que Incluye una mutación de activación. El cáncer es un cáncer de endometrio epitelial o un cáncer de ovario epitelial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939174P | 2019-11-22 | 2019-11-22 | |
| PCT/US2020/061773 WO2021102403A1 (en) | 2019-11-22 | 2020-11-23 | Methods of treating cancer using dkk-1-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006031A true MX2022006031A (es) | 2022-07-19 |
Family
ID=73834617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006031A MX2022006031A (es) | 2019-11-22 | 2020-11-23 | Métodos de tratamiento del cáncer con inhibidores de dkk-1. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240141023A1 (es) |
| EP (1) | EP4061419A1 (es) |
| JP (1) | JP2023502666A (es) |
| KR (1) | KR20220131223A (es) |
| CN (1) | CN114929275A (es) |
| AU (1) | AU2020386091A1 (es) |
| BR (1) | BR112022009708A2 (es) |
| CA (1) | CA3158661A1 (es) |
| IL (1) | IL293090A (es) |
| MX (1) | MX2022006031A (es) |
| WO (1) | WO2021102403A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024015463A1 (en) * | 2022-07-12 | 2024-01-18 | Leap Therapeutics, Inc. | Combination therapy |
| KR20240124222A (ko) * | 2023-02-07 | 2024-08-16 | 제이알디 사이언스, 아이엔씨. | 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5475120A (en) | 1990-11-02 | 1995-12-12 | University Of Florida | Method for the isolation and purification of taxol and its natural analogues |
| US5194635A (en) | 1991-03-18 | 1993-03-16 | Virginia Tech Intellectual Properties, Inc. | Rearranged taxol compounds and method of using in testing of in vivo activity |
| US5416225A (en) | 1992-03-30 | 1995-05-16 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol |
| US5488116A (en) | 1992-03-30 | 1996-01-30 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol and analogues thereof |
| US5440056A (en) | 1992-04-17 | 1995-08-08 | Abbott Laboratories | 9-deoxotaxane compounds |
| WO1993021173A1 (en) | 1992-04-17 | 1993-10-28 | Abbott Laboratories | Taxol derivatives |
| US5461169A (en) | 1992-06-23 | 1995-10-24 | The Scripps Research Institute | Total synthesis of taxol and taxol analogs |
| US5440057A (en) | 1993-08-20 | 1995-08-08 | The Scripps Research Institute | Access to taxol analogs |
| WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
| US5478854A (en) | 1992-10-01 | 1995-12-26 | Bristol-Myers Squibb Company | Deoxy taxols |
| US5411984A (en) | 1992-10-16 | 1995-05-02 | Virginia Tech Intellectual Properties, Inc. | Water soluble analogs and prodrugs of taxol |
| EP0627010A4 (en) | 1992-12-07 | 1995-05-03 | Univ Michigan | PROCESS FOR ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM -i (TAXUS) spp. |
| US5468769A (en) | 1993-07-15 | 1995-11-21 | Abbott Laboratories | Paclitaxel derivatives |
| FR2707642B1 (fr) | 1993-07-16 | 1995-10-13 | Electricite De France | Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques. |
| US5405972A (en) | 1993-07-20 | 1995-04-11 | Florida State University | Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes |
| US5565478A (en) | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| US5508447A (en) | 1994-05-24 | 1996-04-16 | Board Of Regents, The University Of Texas System | Short synthetic route to taxol and taxol derivatives |
| US5489589A (en) | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| AR075989A1 (es) * | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| WO2011109584A2 (en) * | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP3532099A1 (en) * | 2016-10-26 | 2019-09-04 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
-
2020
- 2020-11-23 US US17/779,002 patent/US20240141023A1/en active Pending
- 2020-11-23 IL IL293090A patent/IL293090A/en unknown
- 2020-11-23 WO PCT/US2020/061773 patent/WO2021102403A1/en active Application Filing
- 2020-11-23 MX MX2022006031A patent/MX2022006031A/es unknown
- 2020-11-23 JP JP2022529334A patent/JP2023502666A/ja active Pending
- 2020-11-23 BR BR112022009708A patent/BR112022009708A2/pt unknown
- 2020-11-23 CN CN202080091000.0A patent/CN114929275A/zh active Pending
- 2020-11-23 KR KR1020227020381A patent/KR20220131223A/ko active Search and Examination
- 2020-11-23 EP EP20824401.2A patent/EP4061419A1/en active Pending
- 2020-11-23 CA CA3158661A patent/CA3158661A1/en active Pending
- 2020-11-23 AU AU2020386091A patent/AU2020386091A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114929275A (zh) | 2022-08-19 |
| US20240141023A1 (en) | 2024-05-02 |
| BR112022009708A2 (pt) | 2022-08-09 |
| CA3158661A1 (en) | 2021-05-27 |
| EP4061419A1 (en) | 2022-09-28 |
| WO2021102403A1 (en) | 2021-05-27 |
| KR20220131223A (ko) | 2022-09-27 |
| JP2023502666A (ja) | 2023-01-25 |
| AU2020386091A1 (en) | 2022-06-09 |
| IL293090A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006031A (es) | Métodos de tratamiento del cáncer con inhibidores de dkk-1. | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX2015011362A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| SG11202012585YA (en) | Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use | |
| CR20220646A (es) | Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos | |
| MY192493A (en) | Urinalysis device and dry reagent for quantitative urinalysis | |
| WO2019014328A3 (en) | AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| WO2006113493A3 (en) | Methods of determining cancer prognosis via natural killer cell activity | |
| MX2019008911A (es) | Metodos, matrices y usos de estos. | |
| NZ738875A (en) | Motile sperm domain containing protein 2 and cancer | |
| AU2018286823A1 (en) | Compressible extraction instrument for pretreating a sample | |
| WO2018097614A3 (ko) | 유방암 환자의 화학치료 유용성 예측 방법 | |
| Grassadonia et al. | Long-term outcome of breast cancer patients with pathologic N3a lymph node stage | |
| MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
| MX2020009363A (es) | Un método para detectar magea4. | |
| MX2023002326A (es) | Firma de localizacion celular e inmunoterapia. | |
| Garamszegi et al. | Extracellular matrix-induced gene expression in human breast cancer cells | |
| MX2022000848A (es) | Composiciones amortiguadoras para reducir la agregacion. | |
| Huang et al. | Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer | |
| MX2018015140A (es) | Firmas de biomarcadores de lupus eritematoso sistemico y sus usos. | |
| MX2024007970A (es) | Composiciones y metodos para diagnosticar y tratar la enfermedad renal cronica. | |
| WO2018208749A8 (en) | PROSTATE CANCER GENE PROFILES AND THEIR METHODS OF USE | |
| MX2020011631A (es) | Ensayo de acetaminofeno. | |
| WO2017211893A8 (en) | Biomarker signatures of systemic lupus erythematosus and uses thereof |